Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.
Identifieur interne : 000400 ( PubMed/Checkpoint ); précédent : 000399; suivant : 000401Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.
Auteurs : Birgitte K. Giersing [Suisse] ; Johan Vekemans [Suisse] ; Samantha Nava [États-Unis] ; David C. Kaslow [États-Unis] ; Vasee Moorthy [Suisse]Source :
- Vaccine [ 1873-2518 ] ; 2019.
Abstract
The third meeting of WHO's Product Development for Vaccines Advisory Committee (PDVAC) was held in June 2016, with a remit to revisit the pathogen areas for which significant progress has occurred since recommendations from the 2015 meeting, as well as to consider new advances in the development of vaccines against other pathogens. Since the previous meeting, significant progress has been made with regulatory approvals of the first malaria and dengue vaccines, and the first phase III trials of a respiratory syncytial virus (RSV) vaccine candidate has started in the elderly and pregnant women. In addition, PDVAC has also supported vaccine development efforts against important emerging pathogens, including Middle Eastern Coronavirus (MERS CoV) and Zika virus. Trials of HIV and tuberculosis vaccine candidates are steadily progressing towards pivotal data points, and the leading norovirus vaccine candidate has entered a phase IIb efficacy study. WHO's Immunization, Vaccine and Biologicals (IVB) department is actively working in several pathogen areas on the recommendation of PDVAC, as well as continuing horizon scanning for advances in the development of vaccines that may benefit low and middle income countries (LMICs), such as the recent licensure of the enterovirus 71 (EV71) vaccine in China. Following on from discussions with WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, PDVAC will also look beyond licensure and consider data needs for vaccine recommendation and implementation to reduce the delay between vaccine approval and vaccine impact.
DOI: 10.1016/j.vaccine.2016.10.090
PubMed: 28262332
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28262332Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.</title><author><name sortKey="Giersing, Birgitte K" sort="Giersing, Birgitte K" uniqKey="Giersing B" first="Birgitte K" last="Giersing">Birgitte K. Giersing</name><affiliation wicri:level="1"><nlm:affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author><author><name sortKey="Vekemans, Johan" sort="Vekemans, Johan" uniqKey="Vekemans J" first="Johan" last="Vekemans">Johan Vekemans</name><affiliation wicri:level="1"><nlm:affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author><author><name sortKey="Nava, Samantha" sort="Nava, Samantha" uniqKey="Nava S" first="Samantha" last="Nava">Samantha Nava</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas Medical Branch, Galveston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas Medical Branch, Galveston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Kaslow, David C" sort="Kaslow, David C" uniqKey="Kaslow D" first="David C" last="Kaslow">David C. Kaslow</name><affiliation wicri:level="2"><nlm:affiliation>PATH, Seattle, WA 98109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Moorthy, Vasee" sort="Moorthy, Vasee" uniqKey="Moorthy V" first="Vasee" last="Moorthy">Vasee Moorthy</name><affiliation wicri:level="1"><nlm:affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland. Electronic address: moorthyv@who.int.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:28262332</idno><idno type="pmid">28262332</idno><idno type="doi">10.1016/j.vaccine.2016.10.090</idno><idno type="wicri:Area/PubMed/Corpus">000D59</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D59</idno><idno type="wicri:Area/PubMed/Curation">000D59</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D59</idno><idno type="wicri:Area/PubMed/Checkpoint">000400</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000400</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.</title><author><name sortKey="Giersing, Birgitte K" sort="Giersing, Birgitte K" uniqKey="Giersing B" first="Birgitte K" last="Giersing">Birgitte K. Giersing</name><affiliation wicri:level="1"><nlm:affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author><author><name sortKey="Vekemans, Johan" sort="Vekemans, Johan" uniqKey="Vekemans J" first="Johan" last="Vekemans">Johan Vekemans</name><affiliation wicri:level="1"><nlm:affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author><author><name sortKey="Nava, Samantha" sort="Nava, Samantha" uniqKey="Nava S" first="Samantha" last="Nava">Samantha Nava</name><affiliation wicri:level="2"><nlm:affiliation>University of Texas Medical Branch, Galveston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas Medical Branch, Galveston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Kaslow, David C" sort="Kaslow, David C" uniqKey="Kaslow D" first="David C" last="Kaslow">David C. Kaslow</name><affiliation wicri:level="2"><nlm:affiliation>PATH, Seattle, WA 98109, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Seattle, WA 98109</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Moorthy, Vasee" sort="Moorthy, Vasee" uniqKey="Moorthy V" first="Vasee" last="Moorthy">Vasee Moorthy</name><affiliation wicri:level="1"><nlm:affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland. Electronic address: moorthyv@who.int.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 27</wicri:noRegion></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The third meeting of WHO's Product Development for Vaccines Advisory Committee (PDVAC) was held in June 2016, with a remit to revisit the pathogen areas for which significant progress has occurred since recommendations from the 2015 meeting, as well as to consider new advances in the development of vaccines against other pathogens. Since the previous meeting, significant progress has been made with regulatory approvals of the first malaria and dengue vaccines, and the first phase III trials of a respiratory syncytial virus (RSV) vaccine candidate has started in the elderly and pregnant women. In addition, PDVAC has also supported vaccine development efforts against important emerging pathogens, including Middle Eastern Coronavirus (MERS CoV) and Zika virus. Trials of HIV and tuberculosis vaccine candidates are steadily progressing towards pivotal data points, and the leading norovirus vaccine candidate has entered a phase IIb efficacy study. WHO's Immunization, Vaccine and Biologicals (IVB) department is actively working in several pathogen areas on the recommendation of PDVAC, as well as continuing horizon scanning for advances in the development of vaccines that may benefit low and middle income countries (LMICs), such as the recent licensure of the enterovirus 71 (EV71) vaccine in China. Following on from discussions with WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, PDVAC will also look beyond licensure and consider data needs for vaccine recommendation and implementation to reduce the delay between vaccine approval and vaccine impact.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">28262332</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>50</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.</ArticleTitle><Pagination><MedlinePgn>7315-7327</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(16)31205-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2016.10.090</ELocationID><Abstract><AbstractText>The third meeting of WHO's Product Development for Vaccines Advisory Committee (PDVAC) was held in June 2016, with a remit to revisit the pathogen areas for which significant progress has occurred since recommendations from the 2015 meeting, as well as to consider new advances in the development of vaccines against other pathogens. Since the previous meeting, significant progress has been made with regulatory approvals of the first malaria and dengue vaccines, and the first phase III trials of a respiratory syncytial virus (RSV) vaccine candidate has started in the elderly and pregnant women. In addition, PDVAC has also supported vaccine development efforts against important emerging pathogens, including Middle Eastern Coronavirus (MERS CoV) and Zika virus. Trials of HIV and tuberculosis vaccine candidates are steadily progressing towards pivotal data points, and the leading norovirus vaccine candidate has entered a phase IIb efficacy study. WHO's Immunization, Vaccine and Biologicals (IVB) department is actively working in several pathogen areas on the recommendation of PDVAC, as well as continuing horizon scanning for advances in the development of vaccines that may benefit low and middle income countries (LMICs), such as the recent licensure of the enterovirus 71 (EV71) vaccine in China. Following on from discussions with WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, PDVAC will also look beyond licensure and consider data needs for vaccine recommendation and implementation to reduce the delay between vaccine approval and vaccine impact.</AbstractText><CopyrightInformation>Copyright © 2017 World Health Organization. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giersing</LastName><ForeName>Birgitte K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vekemans</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nava</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Texas Medical Branch, Galveston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaslow</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>PATH, Seattle, WA 98109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moorthy</LastName><ForeName>Vasee</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Initiative for Vaccine Research, World Health Organization, CH-1211 Geneva 27, Switzerland. Electronic address: moorthyv@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>WHO Product Development for Vaccines Advisory Committee</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bacterial</Keyword><Keyword MajorTopicYN="N">LMICs</Keyword><Keyword MajorTopicYN="N">PDVAC</Keyword><Keyword MajorTopicYN="N">Product development</Keyword><Keyword MajorTopicYN="N">SAGE</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword><Keyword MajorTopicYN="N">Viral</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>09</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28262332</ArticleId><ArticleId IdType="pii">S0264-410X(16)31205-1</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.090</ArticleId><ArticleId IdType="pmc">PMC7131228</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15520-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25288770</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2016 Apr 26;13(4):e1001999</Citation><ArticleIdList><ArticleId IdType="pubmed">27115709</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Feb;22(2):224-32</Citation><ArticleIdList><ArticleId IdType="pubmed">26811918</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2016 Jun 3;34(26):2911-2914</Citation><ArticleIdList><ArticleId IdType="pubmed">26973073</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Fam Plann Perspect. 1985 Jul-Aug;17(4):175-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3842809</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308</Citation><ArticleIdList><ArticleId IdType="pubmed">23458769</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2009 Dec 3;361(23):2209-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19843557</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Apr;14(4):308-318</Citation><ArticleIdList><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2010 May 1;375(9725):1545-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20399493</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2015 Dec 08;10(12):e0143304</Citation><ArticleIdList><ArticleId IdType="pubmed">26646541</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2016 Jun 3;34(26):2939-2947</Citation><ArticleIdList><ArticleId IdType="pubmed">27105564</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2016 May 17;34(23):2585-92</Citation><ArticleIdList><ArticleId IdType="pubmed">27079932</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2010 Jun 5;375(9730):1969-87</Citation><ArticleIdList><ArticleId IdType="pubmed">20466419</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2012 Aug;55 Suppl 2:S65-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22752867</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Virol. 2016 Apr;17:138-144</Citation><ArticleIdList><ArticleId IdType="pubmed">27180074</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2019 Nov 28;37(50):7443-7450</Citation><ArticleIdList><ArticleId IdType="pubmed">27916410</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2015 Jan 21;10(1):e114989</Citation><ArticleIdList><ArticleId IdType="pubmed">25608026</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2015 Oct 28;10(10):e0140765</Citation><ArticleIdList><ArticleId IdType="pubmed">26510007</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>mBio. 2016 Jun 07;7(3):</Citation><ArticleIdList><ArticleId IdType="pubmed">27273824</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2016 May 1;62 Suppl 2:S96-S105</Citation><ArticleIdList><ArticleId IdType="pubmed">27059362</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2016 Apr 19;34(18):2082-91</Citation><ArticleIdList><ArticleId IdType="pubmed">26993331</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2016 Jun 3;34(26):2865-2869</Citation><ArticleIdList><ArticleId IdType="pubmed">26993336</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2016 Jul 7;22(7):701-5</Citation><ArticleIdList><ArticleId IdType="pubmed">27387881</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2014 May;22:44-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24631522</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2014 Feb 27;370(9):818-28</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2016 Apr 27;34(19):2170-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27013431</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Vaccin Immunother. 2012 Nov 1;8(11):1585-94</Citation><ArticleIdList><ArticleId IdType="pubmed">22922765</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2015 Oct 10;386(10002):1457-64</Citation><ArticleIdList><ArticleId IdType="pubmed">26142048</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2014 Feb 27;370(9):829-37</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2016 May 7;387(10031):1887-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27203633</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Suisse</li><li>États-Unis</li></country><region><li>Texas</li><li>Washington (État)</li></region></list><tree><country name="Suisse"><noRegion><name sortKey="Giersing, Birgitte K" sort="Giersing, Birgitte K" uniqKey="Giersing B" first="Birgitte K" last="Giersing">Birgitte K. Giersing</name></noRegion><name sortKey="Moorthy, Vasee" sort="Moorthy, Vasee" uniqKey="Moorthy V" first="Vasee" last="Moorthy">Vasee Moorthy</name><name sortKey="Vekemans, Johan" sort="Vekemans, Johan" uniqKey="Vekemans J" first="Johan" last="Vekemans">Johan Vekemans</name></country><country name="États-Unis"><region name="Texas"><name sortKey="Nava, Samantha" sort="Nava, Samantha" uniqKey="Nava S" first="Samantha" last="Nava">Samantha Nava</name></region><name sortKey="Kaslow, David C" sort="Kaslow, David C" uniqKey="Kaslow D" first="David C" last="Kaslow">David C. Kaslow</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000400 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000400 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28262332
|texte= Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28262332" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |